The purpose of this study is to identify an environmentally relevant shared receptor target for endocrine and metabolism disrupting chemical pollutants. A feature of the tested chemicals was that they induced Cyp2b10 in vivo implicating activation of the constitutive androstane receptor (CAR). Recent studies suggest that these compounds could be indirect CAR activators via epidermal growth factor receptor (EGFR) inhibition. Assays included a CAR activity reporter assay, EGF endocytosis assay, and EGFR phosphorylation assay. Docking simulations were used to identify putative binding sites for environmental chemicals on the EGFR. Whole-weight and lipid-adjusted serum mean pollutant exposures were determined using data from the National Health and Examination Survey (NHANES) and compared with the IC 50 values determined in vitro. Chlordane, trans-nonachlor, PCB-126, PCB-153, and atrazine were the most potent EGFR inhibitors tested. PCB-126, PCB-153, and trans-nonachlor appeared to be competitive EGFR antagonists as they displaced bound EGF from EGFR. However, atrazine acted through a different mechanism and could be an EGFR tyrosine kinase inhibitor. EGFR inhibition relative effect potencies were determined for these compounds. In NHANES, serum concentrations of trans-nonachlor, PCB-126, and PCB-153 greatly exceeded their calculated IC 50 values. A common mechanism of action through EGFR inhibition for three diverse classes of metabolic disrupting chemicals was characterized by measuring inhibition of EGFR phosphorylation and EGF-EGFR endocytosis. Based on NHANES data, EGFR inhibition may be an environmentally relevant mode of action for some PCBs, pesticides, and herbicides.
disorders (Heindel et al., 2017) . These classes of chemicals have been linked to many adverse outcomes such as hepatotoxicity, skin rash, developmental disorders, pancreatic dysfunction, and diabetes in humans and animal models (ATSDR, 2000; Emmett et al., 1988; Fischbein et al., 1985; Fischbein et al., 1982; Fischbein et al., 1979; Ju et al., 2009; Reggiani and Bruppacher, 1985; Registry, 1989; Rinsky et al., 2012) . Recently chemical exposures have been found to promote a distinct type of fatty liver disease termed toxicant-associated fatty liver disease (TAFLD) (Cave et al., 2011; Cave et al., 2010b; Wahlang et al., 2013) . TAFLD is perhaps the newest disease associated with EDC/MDC exposures (Heindel et al., 2017) .
The Environmental Protection Agency (EPA) has established the ToxCastDB database to prioritize, screen, and catalog highpriority chemicals using high-throughput receptor activation assays in part to address issues of endocrine disruption (Dix et al., 2007) . The 10 EDCs/MDCs included in the ToxCastDB characterized in this study include atrazine, alachlor, lindane, dieldrin, dichlorodiphenylchloroethane (DDT), dichlorodiphenyldichloroethylene (DDE), trans-nonachlor, chlordane, PCB-153, and PCB-126. These chemicals have previously been characterized as inducers of constitutive androstane receptor (CAR)-dependent gene expression (Kiyosawa et al., 2008; Oshida et al., 2015; Safe et al., 1985; Sakai et al., 2006; Wei et al., 2002) .
These pesticides, herbicides, and PCBs all overlap in their abilities to activate CAR-dependent gene expression, while also exerting adverse effects primarily in the liver, pancreas, skin, and development (ATSDR, 1994; Bondy et al., 2000; Kocarek et al., 1990; Montgomery et al., 2008) . Cyp2b10 induction is an indicator of CAR activation. Direct CAR activation has been shown to be hepatoprotective in NAFLD animal models (Baskin-Bey et al., 2007; Dong et al., 2009; Gao et al., 2009) . Recent investigation of CAR activation has elucidated indirect activation by xenobiotics through epidermal growth factor receptor (EGFR) inhibition leading to CAR dephosphorylation and thus activation (Hardesty et al., 2016; Mutoh et al., 2013) . If the mode of action for environmental chemicals is indirect through EGFR inhibition, multiple signaling pathways would be disrupted potentially countering the protective effects of CAR activation as seen with direct ligand activation (Baskin-Bey et al., 2007; Dong et al., 2009) . These observations add to the complexity of how these compounds elicit their effects while providing some explanation as to why they are hepatotoxic. If these compounds act through EGFR inhibition, this could disrupt a vast signaling cascade essential for hepatic function (Collin de l'Hortet et al., 2014; Hardesty et al., 2016; Komposch and Sibilia, 2016; Natarajan et al., 2007; Robles et al., 2017; Scheving et al., 2014; Scheving et al., 2015) .
EGF signaling in the liver has been found to follow a circadian rhythm that regulates 25% of the hepatocyte proteome activity during the inactive phase (Robles et al., 2017) . It is also important to note that 52% of labeled EGF, the prototypical EGFR ligand, traffics to the liver emphasizing that the liver is a primary internal target organ for EGF uptake (Jorgensen et al., 1988) . It is well documented that cancer patients treated with EGFR inhibitors demonstrate elevated liver enzymes consistent with hepatotoxicity (Fong and Bentrem, 2006; Loriot et al., 2008 ). Animal models demonstrate that loss of EGFR function exacerbates the development of steatosis (Collin de l'Hortet et al., 2014; Scheving et al., 2014) . EGFR is hepatoprotective against chemical-induced liver injury and EGF supplementation protects against alcohol-induced liver inflammation (Deaciuc et al., 2002; Komposch and Sibilia, 2016) . EGFR signaling is also important for insulin secretion in b-islets and EGFR inhibitors diminished insulin output in cancer patients (Fountas et al., 2015; Lee et al., 2008b; . Dermal rashes upon exposure to pharmaceutical EGFR inhibitors, dioxins, PCBs, chlorinated pesticides, and herbicides are well-documented adverse effects common between these classes of compounds (ATSDR, 1994 (ATSDR, , 2002a (ATSDR, , 2002b CDC, 1992; Dikshith, 2003; Emmett et al., 1988; Fischbein et al., 1985; Fischbein et al., 1982; Holcmann and Sibilia, 2015; Mascia et al., 2013; Reggiani and Bruppacher, 1985) . Loss of EGFR function in mice leads to skin inflammation suggesting the importance of EGFR function for skin homeostasis and wound healing (Campbell et al., 2014; Holcmann and Sibilia, 2015; Lichtenberger et al., 2013; Mascia et al., 2013) . PCB exposure in pregnant women has been shown to diminish placental EGFR phosphorylation which correlated with lower birth weights . EGFR is instrumental in development, and homozygous EGFR-null mice do not survive past postnatal day 20 (majority die on postnatal day 1) and have severe abnormalities (Hansen et al., 1997; Miettinen et al., 1995; Miettinen et al., 1999) . These previous studies serve to illustrate the multiple adverse effects due to inhibition of EGFR signaling in the liver, b-islets of the pancreas, skin, and during development. With the literature demonstrating that the selected EDCs/MDCs are CAR activators, their mode of action has not been firmly established. Therefore, compounds in this study were investigated to determine if they directly activate CAR or act through EGFR inhibition. Should the selected pollutants inhibit EGFR function at environmentally relevant concentrations, then the impact of their signaling disruption on human health and disease could be evaluated in future studies.
MATERIALS AND METHODS
Compound selection. A set of 10 MDCs/EDCs known to activate CAR were selected from high priority chemicals identified in NHANES or ToxCastDB. These chemicals included trans-nonachlor, chlordane, DDE, DDT, dieldrin, alachlor, atrazine, lindane, PCB-153, and PCB-126. Trans-nonachlor and DDE were purchased from SUPELCO (Bellefonte, PA). Lindane and DDT were purchased from CHEM Service (West Chester, PA). Dieldrin, chlordane, atrazine, and alachlor were purchased from Sigma Aldrich (St. Louis, MO). PCB-153, a non-dioxin like PCB and PCB-126, a dioxin-like PCB, were purchased from AccuStandard (New Haven, CT).
Plasmid construction. mCAR cDNA was a generous gift from Tom Rushmore (Merck Research Laboratories, West Point, PA) which was subcloned into a modified version of pGL3-basic (Falkner et al., 1998; Hardesty et al., 2016) . Mice lack CAR splice variants found in humans but the mCAR is 89% homologous to hCAR1. Restriction endonucleases and T4 DNA ligase were purchased from New England BioLabs (Ipswich, MA). Dimethyl sulfoxide (DMSO) was purchased from Fisher BioReagents (Thermo Fisher Scientific, Pittsburg, PA). Lipofectamine and Opti-MEM were acquired from Life Technologies Inc. (Carlsbad, CA). Oligonucleotides were purchased from Integrated DNA Technologies (Coralville, IA).
Cell culture. HepG2 Cells: The human hepatoma-derived cell line (HepG2) derived from a male patient was obtained from American Type Culture Collection (ATCC, Manassas, MD). Cells were grown in Dulbecco's modified Eagle's medium (DMEM; HyClone Laboratories Inc., Thermofisher, Waltham, MA) supplemented with 10% fetal bovine serum (FBS) and 1% antimycotic/ antibiotic solution (Mediatech, Manassas, VA). The cells were incubated in a 5% carbon dioxide atmosphere and 95% humidity at 37 C and subcultured every 2 days. Luciferase reporter assay. Cells were washed twice with phosphate-buffered saline (PBS 1Â), harvested using 50ll cell lysis buffer (Promega, Madison, WI) and subjected to a single freezethaw event. For b-galactosidase assays, cell extracts (5 ml), were incubated with chlorophenol red b-galactopyranoside (CPRG, Sigma-Aldrich) at 37 C for 30-60 min. The enzyme activity was measured spectrophotometrically at 595 nm using the Bio-Tek Synergy HT multi-mode micro plate reader. Luciferase activity assays were performed on cell extracts (5 ll) using the Luciferase Assay System (Promega). Luminescence was measured using the Orion L micro plate luminometer (Berthold Detection Systems, Pforzheim, Germany) over a 10-s period. Receptor activation was measured by luciferase activity and results were normalized to the amount of b-galactosidase expressed.
EGF assay in HepG2 cells. Cells were pretreated with 10 lM (this concentration was found to not be cytotoxic in MTT assays, Supplementary Figure 3 ) (or 4.1 lg/ml for the chlordane mixture) of the compound of interest for 10 min followed by 30 min with 20 ng/ml of EGF (Fisher Scientific, Pittsburgh, PA). EGF alone for 30 min was used as a positive control, and 30-min treatment with 0.1% DMSO was used as a negative control. The 30-min treatment was used as that was the peak time for EGFR phosphorylation (Hardesty et al., 2016) . The positive and negative controls were used to establish phosphorylated EGFR's dynamic range. Media was removed by aspiration and the cells were washed with PBS. Cells were lysed in modified radioimmunoprecipitation assay (RIPA) buffer (20 mM Tris, 150 mM NaCl, 1 mM EDTA/EGTA/b-glycerophosphate/Na 3 VO 4 , and 1% Triton X-100) supplemented with protease and phosphatase inhibitors (Sigma-Aldrich).
EGF endocytosis assay in A-431 cells. This assay was modified from a previously described method (Wang and Xie, 2007) . A-431 cells were used as they express 2.6 Â 10 6 EGFRs per cell (Haigler et al., 1978) . Alexa Fluor 555 labeled EGF was purchased from Thermo Scientific (Philadelphia, PA) and was used at 20 ng/100 ll. After a 3-h serum starvation, A-431 cells were exposed to varying concentrations of the compounds (10 À19 -10 À3 M) for 10 min. Since chlordane is a mixture, it was administered at the following concentrations 0.41 Â 10 À16 to 41 lg/100 ll.
The chlordane competition curve is in the logarithmic scale for ease of comparison. Positive control cells were treated with 0.1% DMSO and negative control cells were treated with 20 ng/ 100 ll of unlabeled EGF purchased from Millipore (Norwood, OH). This served as a negative because the EGF receptors would be saturated and endocytosed preventing fluorescently labeled EGF from binding thus preventing any signal. Cells were then treated with 20 ng/100 ll of Alexa Fluor 555 labeled EGF for 30 min. This was followed by 3 washes with pre-warmed PBS and incubation with 3.7% formaldehyde for 15 min. Cell nuclei were then stained with Hoechst 33342 purchased from Thermo Scientific (Philadelphia, PA) at 1 lg/100 ll for 15 min. Images and data were obtained via an ArrayScan HCS 4.0 Reader (ThermoSceintific, Philadelphia, PA). Filter sets specific for Hoechst labeled nuclei and the Alexa Fluor 555-EGF were used for detection. A 20Â microscope objective was used for imaging and the SpotDetector bioapplication was used to acquire and analyze images. Approximately 500 cells from randomized fields were analyzed for each well. The equation used to normalize 555-EGF count/nuclei values is listed below.
Alexa Fluor 555 EGF Endocytosis
To determine if these compounds could displace 555-EGF from the ligand binding domain of EGFR, cells were pretreated with 20 ng/100 ll of Alexa Fluor 555-EGF for 2.5 min on ice to prevent endocytosis. Cells were then exposed to 1 pM of (PCB-126, PCB-153, trans-nonachlor) 0.041 pg/100 ll of chlordane and 100 pM of atrazine for 2.5 min on ice. The plated cells were incubated at 37 C for 25 min and the assay was continued as previously described. The relative effect potencies (REPs) were calculated from the normalized IC 50 values from the EGF endocytosis assay for the compounds tested (normalized to trans-nonachlor, most potent).
Western blot analysis. Cell culture lysates from HepG2 and A-431 cells were homogenized in RIPA buffer (150 ll RIPA supplemented with protease, and phosphatase inhibitors 10 ll/ml (Sigma-Aldrich). The protein concentration was determined by bicinchoninic acid protein assay (Sigma-Aldrich). Protein (15 lg) was separated on 7.5% SDS Gel (BioRad, Hercules, CA), transferred to polyvinylidene difluoride membranes and blocked in PBS, pH 7.5 containing 0.1% Tween 20 (PBS-T), and 5% fat-free milk for 1 h at room temperature. Membranes were incubated at 4 C overnight with primary antibody at 1:1000 dilution in 5% bovine serum albumin in PBS-T, then washed 4 times with PBS-T for 5 min followed by incubation with secondary antibody 1:2000 in 5% milk in PBS-T (Cell Signaling Technology, Danvers, MA). After 4 PBS-T washes, the membranes were incubated with ECL (Thermo Scientific, Waltham, MA) and luminescent signals were captured with BioRad Chemidoc Imaging System.
Western blot protein bands were quantified using BioRad Image Software (Hercules, CA). For detection of phosphoproteins, the phospho-antibody blots were stripped for 15 min (Thermo Scientific, Waltham, MA) and then re-probed using primary antibody against total protein overnight in 5% fat-free milk in PBS-T. Antibodies for p-EGFR Y1173 were obtained from Abcam (Cambridge, MA). The antibody for EGFR was purchased from Santa Cruz (Santa Cruz, CA). Antibodies for p-ERK1/2 and ERK1/2 were purchased from Cell Signaling Technology (Danvers, MA).
Molecular modeling and docking simulation. The inactive EGFR structure (INQL) and select chemicals from PubChem were prepared using Chimera (Ferguson et al., 2003; Kim et al., 2016; Moustakas et al., 2006) . Docking simulations were conducted using AutoDock Vina, and the predicted sites with the best scores were further analyzed. The top two ligand positions were selected based on their root-mean-square deviation lower and upper bound metrics. The EGFR tyrosine kinase structure (4HJO) was used for docking simulations for atrazine (Park et al., 2012 Statistical analysis. All statistical analyses were performed using GraphPad Prism version 7 for Macintosh (GraphPad Software Inc., La Jolla, CA). Data are expressed as mean 6 SEM. Multiple group data were compared using one-way ANOVA followed by Bonferroni's post hoc test for parametric data for all pairwise comparisons. p <.05 was considered statistically significant. Competitive binding curves and IC 50 values were calculated with Graphpad Prism 7 using two sites-Fit logIC 50 . Two group comparisons were made using a two-tailed unpaired t-test and a p < .05 was considered statistically significant.
RESULTS
Selected Compounds Do Not Appear to Be Direct Agonists of CAR, but Trans-Nonachlor, Chlordane, and Atrazine Inhibit EGF Stimulated Y1173 Phosphorylation of EGFR To determine whether previously characterized CAR activators were direct CAR activators, a DR4-luciferase reporter in HepG2 cells co-transfected with mCAR was used. The assay was performed for the following compounds: atrazine, dieldrin, transnonachlor, lindane, alachlor, chlordane, DDT, and DDE, at 10 lM to evaluate their ability to directly activate CAR. PCB-126 and PCB-153 were not used for this assay as the results have already been published and both were found to ablate EGF-mediated EGFR phosphorylation (Hardesty et al., 2016) . If the compounds act as direct activators of mCAR, then they should increase luciferase activity similarly to TCPOBOP ( Figure 1A ). As anticipated, TCPOBOP increased reporter signal by 2.6-fold, which is in good agreement with our previous work and others (Hardesty et al., 2016; Tzameli et al., 2000) . None of the compounds significantly increased the reporter expression even though in vivo studies demonstrate that they induce Cyp2b10. CAR has been shown to be indirectly activated through inhibition of EGFR signaling (Mutoh et al., 2013) . In Figure 1B , compounds that can prevent EGF stimulation of EGFR in HepG2 cells were identified. The EGF assay in HepG2 cells was performed with the same chemicals previously used at 10 lM concentration for 10 min followed by EGF at 20 ng/ml for 30 min. and pGL3-DR4-Luc constructs and exposed to each compound at 10 lM, 0.1% DMSO was used as a negative control, and TCPOBOP (direct mCAR agonist) was used as positive control. The data are presented as mean 6 SEM and n ¼ 4 was used. *p < .05. B, HepG2 cells were pre-exposed to the select compounds at 10 lM for 10 min before EGF administration at 20 ng/ml for the experimental groups for 30 min. 0.1% DMSO and EGF-treated cells served as the negative and positive controls, respectively. EGFR phosphorylation at Y1173 was measured via western blot analysis and was normalized to total EGFR. n ¼ 4 was used and the values are represented as mean6SEM for (A) and (B). Experimental values were compared with EGF alone values by a one-way ANOVA for (B). * p < .05; **** p < .0001; both considered statistically significant. Abbreviations: ANOVA, analysis of variance; CAR, constitutive androstane receptor; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor.
Compared with EGF alone, atrazine, chlordane, and trans-nonachlor all substantially diminished EGF stimulation of EGFR phosphorylation: 73% for atrazine (p < .02) and 82% for transnonachlor (p < .01) and chlordane (p < .01). DDE, DDT, dieldrin, alachlor, or lindane did not significantly alter EGFR phosphorylation in the presence of EGF ( Figure 1B ). Indirect CAR activation by these compounds may occur through uncharacterized EGFRindependent mechanisms. These experiments suggested that chlordane, trans-nonachlor, and atrazine were indirect CAR activators possibly acting through EGFR inhibition. Chlordane, trans-nonachlor, and atrazine were chosen to investigate further along with previously characterized EGFR signaling disruptors PCB-126 and PCB-153 (Hardesty et al., 2016) .
Trans-Nonachlor, Chlordane, PCB-126, PCB-153, and Atrazine Prevent EGF Endocytosis in A-431 Cells To determine whether select compounds prevent EGF endocytosis, a competition assay in human A-431 cells using Alexa Fluor 555-EGF (20 ng/100 ll or 32 nM) and increasing concentrations of the select compounds and non-labeled EGF (10 À19 -10 À3 M) was conducted. Fluorescently labeled EGF in the absence of an inhibiting compound will bind the EGFR leading to dimerization and endocytosis. The amount of fluorescent signal per cell is a measure of EGF-EGFR endocytosis, and EGF binding in the presence of varied concentrations of these compounds. If fluorescently labeled EGF is incapable of binding the EGFR, there will be no to low fluorescent signal per cell indicating a lack of EGF binding and/or dimerization and endocytosis. This concentration of Alexa Fluor 555-EGF was used as it was previously shown to give robust signal in the Cellomics assay (Wang and Xie, 2007) . The EGFR has two conformational states that have different affinities for EGF Ozcan et al., 2006; Sunahara et al., 1987) . The lower affinity state is most likely the unliganded monomer, whereas the high affinity state is probably unliganded, preformed dimers and/or tetramers (Needham et al., 2016; Ozcan et al., 2006) . Thus, the biphasic competition curves likely reflect these two affinity states where the first IC 50 value is the low affinity state (EGFR monomer) and the second IC 50 is the high affinity state (preformed EGFR dimers or tetramers) of the EGFR. Figure 2A shows non-labeled EGF's ability in preventing fluorescent EGF endocytosis and EGF's IC 50 value was log À15.460.31 M for the high affinity site and log À8.9960.6 M for the low affinity site. Figure 2B shows that the IC 50 value for prevention of EGF endocytosis by chlordane was log À16.4960.33 M (0.0013 fg/100 ll) for the high affinity site and log À4.060.54 M (4.1 lg/100 ll) for the low affinity site. Figure 2C shows the IC 50 value for loss of EGF endocytosis due to transnonachlor of log À16.660.23 M for the high affinity site and log À3.8860.72 M for the low affinity site. Figure 2D shows IC 50 values for loss of EGF endocytosis due to PCB-126 to be log À16.0760.31 M for the high affinity site and log À8.3860.24 M for the low affinity site. Figure 2E shows the IC 50 values for PCB-153 of the loss of EGF endocytosis being log À12.460.2 M for the high affinity site and log À5.2660.49 M for the low affinity site. Atrazine's IC 50 value for loss of EGF endocytosis was log À10.4260.34 M for the high affinity site and log À3.5160.95 M for the low affinity site ( Figure 2F ). These findings suggest that chlordane, trans-nonachlor, PCB-126, PCB-153, and atrazine are potent EGFR antagonists that prevent EGF endocytosis.
REPs and NHANES Serum Concentrations for Trans-Nonachlor, PCB-126, and PCB-153
In this study, the data gathered was used to develop REPs for EGFR inhibiting compounds. REPs are used to rank chemicals based on their potency to activate or inhibit a receptor and in turn that value is used for risk assessment based on the individual's additive body burden of multiple chemicals ( , and atrazine's REP was 7.9 Â 10 À6 . The mean lipid-adjusted and wet weight serum concentrations for trans-nonaclor, PCB-126, and PCB-153 in NHANES 1999-2004 participants are given in Table 2 (CDC, 2009 ). The mean trans-nonachlor lipid adjusted concentrations ranged from 18.3 to 14.7 ng/g (41-31 nM) and decreased over time. The trans-nonachlor wet weight means ranged from 0.11-0.09 ng/g (248-203 pM) and were higher than the IC 50 for EGFR inhibition (0.03 fM). PCB-126 mean lipid adjusted concentrations varied from 0.023 to 0.016 ng/g (71-50 pM) and decreased over time. The PCB-126 wet weight mean varied between 0.00015 and 0.0001 ng/g (460-307 fM), and was higher than the IC 50 for EGFR inhibition (0.09 fM). The PCB-153 mean lipid adjusted concentration was 27.2-19.8 ng/ g (75-55 nM) and decreased over time. The PCB-153 wet weight mean ranged from 0.17 to 0.12 ng/g (471 to 332 pM), and was greater than the IC 50 for EGFR inhibition (363 fM). These data demonstrate that the levels measured in humans may be relevant for future investigation of adverse effects due to EGFR inhibition by these chemicals.
Trans-Nonachlor, Chlordane, PCB-126, PCB-153, and Atrazine Prevent EGF-Mediated EGFR and ERK Phosphorylation in A-431 Cells at the IC 50 Concentration
To determine if exposure to the respective IC 50 values for these compounds would diminish EGFR phosphorylation and downstream signaling, EGFR Y1173 and ERK phosphorylation were measured at the IC 50 concentrations previously determined by the EGF endocytosis assay. A-431 cells were pretreated with compounds at the respective IC 50 values followed by a 30-min treatment with EGF at 20 ng/ml. Protein was then extracted and western blot analysis was conducted to measure phosphorylation of EGFR and effector kinase ERK1/2 (Figs. 3A and 3B). Chlordane (p < .02, p < .02), trans-nonachlor (p < .019, p < .05), PCB-126 (p < .02, p < .05), PCB-153 (p < .03, p < .03), and atrazine (p < .03, p < .05) exposure significantly diminished EGFR and ERK phosphorylation, respectively, at their respective IC 50 values. These results demonstrate that these compounds can prevent EGF-mediated EGFR phosphorylation and downstream signaling.
Trans-Nonachlor, Chlordane, PCB-126, and PCB-153 Can Displace Bound 555-EGF From the EGFR but not Atrazine Next, to determine if these compounds act as competitive inhibitors that can displace bound fluorescent EGF from the ligandbinding domain of the EGFR, a competition assay with fluorescent EGF administration before the chemical was conducted. A-431 cells on ice were treated with 20 ng/100 ll of Alexa-Fluor 555-EGF for 2.5 min and then exposed to 1 pM of either PCB-126, PCB-153, trans-nonachlor, chlordane (0.041 pg/100 ll), or 100 pM of atrazine for 2.5 min. Cells were then incubated at 37 C for 25 min to continue the endocytosis reaction (Figure 4 ). Chlordane (p < .0002), trans-nonachlor (p < .0001), PCB-126 (p < .0001), and PCB-153 (p < .0008) were all able to significantly displace fluorescent EGF from interaction with EGFR similarly to non-labeled EGF. Atrazine (p < .94) was unable to displace fluorescent EGF from its interaction with the EGFR and had similar signal intensity as seen with the DMSO positive control. These findings would suggest that chlordane, trans-nonachlor, PCB-126, and PCB-153 are competitive antagonists, whereas atrazine appears to be an EGFR antagonist that cannot prevent EGF endocytosis once already bound. (4HJO) were used for the docking simulations (Ferguson et al., 2003; Park et al., 2012) . This allowed for the identification of where the various chemicals are predicted to bind in the single monomer state of the EGFR. As seen in Figure 5A , trans-nonachlor was predicted to bind within a hydrophobic pocket between domains II and IV (red) and domain IV (blue) of EGFR with an affinity of À5.8 kcal/mol for both sites. PCB-126 was predicted to bind within a hydrophobic pocket of domain III (red) and domain II (blue) with an affinity of À6.1 and À5.9 kcal/mol, respectively ( Figure 5B ). PCB-153 was predicted to bind within a hydrophobic pocket between domain II and IV (red) of and domain IV (blue) of EGFR with an affinity of À5.9 and À6.1 kcal/mol, respectively ( Figure 5C ). In striking contrast, atrazine was predicted to interact within the tyrosine kinase domain in the ATP-binding pocket with an affinity of À5.6 kcal/mol (red) and at another site within the TK domain at À5.5 kcal/mol (blue) ( Figure 5D ). The interacting residues within each binding pocket are listed in Table 3 .
DISCUSSION
Initially, the well-characterized CAR-activating chlorinated compounds were determined to not directly activate mCAR relative to the direct mCAR ligand, TCPOBOP in cell culture. This led to the evaluation of their potential roles as EGFR inhibitors that possibly indirectly activate CAR through phosphorylation as has been previously demonstrated for phenobarbital and PCBs (Hardesty et al., 2016; Mutoh et al., 2013) . Interestingly trans-nonachlor, chlordane, and atrazine all had a significant effect in preventing EGF-mediated EGFR phosphorylation in Chlordane, trans-nonachlor, (A-B) PCB-126, PCB-153, and atrazine prevent EGF-mediated phosphorylation at the IC50 value from the EGF endocytosis assay. To test whether EGFR Y1173 and ERK phosphorylation was diminished concordantly at the measured IC50 for loss of EGF endocytosis, A-431 cells were exposed to the IC50 concentration for the respective compounds and EGFR Y1173 and ERK phosphorylation were measured via western blot analysis after EGF treatment. n ¼ 4 was used and values are represented as mean6SEM. Quantitated band densities were statistically compared with the EGF positive control values by an unpaired, two-tailed ttest. * p<.05 which is considered statistically significant. Abbreviations: EGF, epidermal growth factor; EGFR, epidermal growth factor receptor.
HepG2 cells. At this stage, these compounds were investigated further to understand how they act on the EGFR. The EGFR has 4 sequential and highly regulated steps for activation including (1) EGF binding to an inactive EGFR monomer generating an active monomer, (2) homo or heterodimerization of ligand bound monomers, (3) autophosphorylation by the tyrosine kinase domain, and (4) endocytosis (Citri and Yarden, 2006; Ward et al., 2007) . Using these regulatory steps of EGFR activation, the experimental design was developed to investigate at what step these chemicals are eliciting their inhibitory effects. The fluorescent EGF assay was used to measure EGF-EGFR endocytosis in the presence of the chemicals tested. Subsequently, the effect of these chemicals on EGFR phosphorylation was determined by western blot analysis. These assays paired with the structural modeling were used to determine how these chemicals ablate EGFR signaling.
Previously published studies in cell-based competition assays have determined that there are low and high affinity sites for EGF binding Ozcan et al., 2006; Sunahara et al., 1987) . Currently, it is hypothesized that roughly 10% of EGF receptors are in the high affinity conformation which are either preformed non-liganded dimers or potentially tetramers (Krall et al., 2011; Needham et al., 2016) . The other 90% of EGF receptors are hypothesized to be in the single monomer conformation or the low affinity state. This is an important concept as the concentration curves from the fluorescent EGF assay demonstrate two-site binding which may be representative of a low affinity and high affinity conformation of the EGFR. The data presented suggest that the amount of high affinity receptors may have been previously underestimated at 10%. Collectively, the data suggest that the amount of high affinity receptors in the A-431 cells may be as high as 30% of the total receptors. The low affinity site seems more sensitive to EGF than in previous studies. This may be due to differences in the EGF label (fluorescent vs. radiolabeled) and the reaction temperature (37 C vs. 4 C) (Fernandez-Pol, 1985) .
While trans-nonachlor, PCB-126, PCB-153, and atrazine were potent at preventing EGF endocytosis, confirmation that the phosphorylation cascade was disrupted was necessary to validate these compounds as EGFR signaling disrupting chemicals (SDCs). At the respective concentrations of the IC 50 values for the chemicals, both EGFR phosphorylation and ERK1/2 phosphorylation were reduced. This demonstrated that multiple steps of the EGFR activation mechanism were prevented by exposure to these compounds.
The EGF displacement assay demonstrated that trans-nonachlor, PCB-126, PCB-153, and chlordane can apparently displace bound fluorescent EGF from interacting with the EGFR. This suggests that these compounds are competitive antagonists that interact with the extracellular domain of the EGFR. Further ligand-receptor docking studies found that trans-nonachlor, PCB-126, and PCB-153 interact with hydrophobic residues within the extracellular domain of EGFR. Interestingly, atrazine could not compete off bound EGF from EGFR, and thus it may bind within the ATP pocket of the tyrosine kinase domain of EGFR and not at the hydrophobic pocket between domains II and IV of EGFR. Since these compounds are structurally diverse and EGFR has multiple regulatory activation steps, it seems logical that environmental chemicals could differ in their method of EGFR inhibition. Atrazine appeared to act as a tyrosine kinase inhibitor as EGF was able to stay bound in the presence of atrazine.
Although some of the compounds tested were not potent EGFR inhibitors including lindane, DDE, DDT, alachlor, and dieldrin, this does not rule out the possibility that these compounds could disrupt the signaling of other related receptor tyrosine kinases (RTKs). This has already been demonstrated for phenobarbital and the insulin receptor (Yasujima et al., 2016) . Since many RTKs have highly homologous tyrosine kinase domains, the downstream effects of receptor inaction could overlap (Robinson et al., 2000; Zwick et al., 2001) .
Although the EGF endocytosis assay was previously published as a tool for high-throughput EGFR inhibitor screening for EGFR-directed chemotherapy discovery, it may also serve as a chemical adverse effect screen (Wang and Xie, 2007) . Fifty-two percent of exogenously administered EGF traffics to the liver in animals, and recently EGFR signaling has been shown to regulate 25% of the liver phosphoproteome during the inactive phase in mice (Jorgensen et al., 1988; Robles et al., 2017) . EGFR signaling is essential not only in liver homeostasis, but in the pancreas as well. EGFR signaling promotes insulin secretion in b-cells and insulin levels have been observed to be decreased in patients administered EGFR inhibitors (Lee et al., 2008a (Lee et al., , 2008b Miettinen et al., 2008; Prada et al., 2017) . EGFR inhibition or loss of function is linked to the development of skin rashes and skin inflammation (Campbell et al., 2014; Holcmann and Sibilia, 2015; Lichtenberger et al., 2013; Mascia et al., 2013; Sibilia et al., 2003) . In fact, some of the compounds tested in this study cause a skin rash and related toxic responses upon exposure which is commonly referred to as chloracne (Emmett et al., 1988; Fischbein et al., 1979 Fischbein et al., , 1982 Fischbein et al., , 1985 Ju et al., 2009; Reggiani and Bruppacher, 1985; Registry, 1989) . This chloracne may be mechanistically distinct from the chloracne observed in people exposed to high levels of TCDD. EGFR signaling is also crucial in development and is highly expressed in the placenta. Diminished placental EGFR phosphorylation was observed in Yu-cheng women exposed to PCBs which correlated to lower birth weights Sunahara et al., 1987) . Since EGFR signaling is physiologically relevant in liver, pancreas, skin, and in utero development, this receptor-internalization assay should be considered for screening new chemical compounds for adverse health effects. Many EPA high-throughput screens focus on chemicalinduced modulation of nuclear receptor activity, but new assays for RTKs should be considered as well. Since RTK activity regulates almost every facet within the cell including nuclear receptor activity, they should also be considered in adverse outcome chemical testing. The data demonstrate that although the Atrazine was modeled with the inactive EGFR RTK domain (4HJO). The EGFR structure and compounds were prepared in Chimera and docking simulations were conducted using AutoDock Vina software. The models show the two most energetically favorable sites and the hydrophobicity of the amino acids within those predicted sites. Abbreviation: EGFR, epidermal growth factor receptor.
structures of these compounds are diverse, they act through EGFR inhibition. This may allow for an additive risk assessment between these different classes of compounds for a variety of maladies including liver disease, pancreatic dysfunction, skin irritation, and developmental defects. Future in vivo studies will evaluate whether the compounds tested promote endocrine and metabolic disruption in an EGFR-dependent manner.
The mean serum levels of trans-nonachlor, PCB-126, and PCB-153 in NHANES demonstrate that many people in the general population may be at risk for EGFR inhibition by environmental chemicals. The IC 50 values shown for the various EGFR inhibitors appear low and similar too or less than the human serum concentrations of these compounds. As these compounds are hydrophobic, with very high hexane: water partition coefficients, these compounds will accumulate on the cell surfaces of the monolayer rather than being evenly distributed in the culture media. Likewise, the in vivo distribution of these compounds is very dependent on the pharmacokinetics of body distribution, being much higher in adipose and potentially fatty liver. Thus, the observed IC 50 may be considerably lower than the serum concentration that is likely to manifest itself as EGFR inhibition in vivo. Future work is needed to establish what serum concentrations of these chemicals elicit EGFR inhibition in varied tissues in vivo leading to adverse effects.
Current risk assessment measures for adverse effects due to environmental exposures are limited. For dioxins acting through the aryl hydrocarbon receptor, toxic equivalency factors (TEFs) and toxic equivalencies (TEQs) have been determined, in part, through REP data (van Ede et al., 2016) . TEQ allows for analysis of the health effects of mixtures of dioxins with varying potencies. REPs for some environmental chemicals inhibiting EGFR were generated in this manuscript. Since the fluorescent EGF assay is high throughput, it may serve as a preliminary toxicity evaluation tool for other chemicals, generating additional REPs. If EGFR inhibition by environmental chemicals is additive, TEFs and TEQs for EGFR inhibiting chemicals could be generated in the future to aid in the evaluation of complex mixtures of these chemicals. We propose that this could be done in a fashion similar to what was developed for dioxins.
CONCLUSION
This study demonstrates that EGFR inhibition is a conserved mechanism for diverse EDCs/MDCs that were previously characterized as CAR activators. The high-throughput methods used in this investigation may provide a model system for adverse outcome evaluation of new chemicals being manufactured. PCB-126, PCB-153, and trans-nonachlor are likely competitive antagonists of EGF binding to EGFR. In contrast, atrazine appears to act as a tyrosine kinase inhibitor that was predicted to bind to the ATP pocket of the EGFR TK domain. The predicted binding sites are indicative of hydrophobic interactions with nonpolar amino acids of the EGFR. These findings are summarized in the Graphical Abstract. Furthermore, this study establishes human-specific REPs for EGFR SDCs and documents two mechanisms for this inhibition. Future studies should determine if atrazine, trans-nonachlor, and chlordane diminish EGFR signaling in vivo similar to PCBs (Hardesty et al., 2016) . Epidemiological studies should test whether exposure to these SDCs have additive risk for developmental, dermatological, and metabolic diseases. Abbreviation: EGFR, epidermal growth factor receptor.
